Physician profile
Steven Sobel
NPI 1467489864
$6,856.52
in general payments reported to CMS, 2019-2025
25 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $258 · 2021: $992 · 2022: $1,255 · 2023: $971 · 2024: $970 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,942 · Entertainment: $113 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.29 |
| Entertainment | $112.89 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,029.74 | 2019-2025 | Dailies Total1, Clareon, Tryptyr |
| Coopervision INC. | $1,022.41 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $655.27 | 2019-2021 | |
| Oyster Point Pharma, INC. | $564.08 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $556.91 | 2022-2025 | Vyzulta, Miebo, Infuse |
| Harrow Eye, LLC | $375.80 | 2024-2025 | Vevye |
| Abbvie INC. | $339.74 | 2022-2023 | Vuity |
| Kala Pharmaceuticals, INC. | $318.22 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $265.17 | 2019-2023 | Cequa |
| Optos, INC. | $246.07 | 2021-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $216.47 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $178.55 | 2024-2025 | Xdemvy |
| Allergan, INC. | $173.03 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $168.73 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $153.54 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $140.40 | 2019 | |
| Dompe US, INC. | $102.22 | 2023-2025 | Oxervate |
| Notal Vision, INC. | $87.95 | 2024-2025 | Foresee Home |
| Optovue, INC. | $75.60 | 2019 | |
| Eyevance Pharmaceuticals LLC | $44.04 | 2019-2022 | |
| Biotissue Holdings INC. | $43.52 | 2021-2024 | |
| Visionix USA, INC | $40.00 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $20.76 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $19.55 | 2022 | |
| Sight Sciences, INC. | $18.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.